Chidamide inhibits cell glycolysis in acute myeloid leukemia by decreasing N6-methyladenosine-related GNAS-AS1.
Acute myeloid leukemia
Chidamide
GNAS-AS1
Glycolysis
MiR-34a-5p
N6-Methyladenosine
Journal
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
ISSN: 2008-2231
Titre abrégé: Daru
Pays: Switzerland
ID NLM: 101125969
Informations de publication
Date de publication:
06 Nov 2023
06 Nov 2023
Historique:
received:
30
05
2023
accepted:
10
09
2023
medline:
6
11
2023
pubmed:
6
11
2023
entrez:
5
11
2023
Statut:
aheadofprint
Résumé
Acute myeloid leukemia (AML) is a hematopoietic malignancy. Chidamide has shown anti-cancer effect in different malignancies. The function of Chidamide in glycolysis in AML cells remains unclear. AML cells were treated with 1000 nM Chidamide for 48 h. The levels of long non-coding RNA-GNAS-AS1, miR-34a-5p, glycolysis-related proteins, and Ras homolog gene family (RhoA)/Rho-associated protein kinase (ROCK) signaling-related proteins were detected by qRT-PCR or western blot. Cell viability and apoptosis were measured by CCK-8 and flow cytometry. Glycolysis levels were measured by assay kits. GNAS-AS1 N6-methyladenosine (m6A) modification level was detected by methylated RNA immunoprecipitation sequencing. The combined targets of miR-34a-5p were validated using a dual-luciferase reporter assay. BALB/C nude mice were selected for subcutaneous tumor validation. Chidamide at a dosage of 25 mg/kg was used in the animal study. GNAS-AS1 promoted glycolysis in AML cells by upregulating the expression of glycolysis-related proteins and increasing glucose consumption, lactate production, ATP generation, and the extracellular acidification rate. Chidamide treatment suppressed WT1-associated protein (WTAP)-mediated RNA m6A modification of GNAS-AS1. Chidamide downregulated GNAS-AS1 to inhibit glycolysis in AML cells. GNAS-AS1 targeted miR-34a-5p to promote insulin-like growth factor 2 mRNA-binding protein (IGF2BP2) expression. IGF2BP2 inhibition reversed the promoting effect of miR-34a-5p knockdown on glycolysis and RhoA/ROCK pathway in Chidamide-treated cells. GNAS-AS1 overexpression abolished the inhibitory effect of Chidamide on AML tumorigenesis in vivo by modulating the RhoA/ROCK pathway. Chidamide inhibited glycolysis in AML by repressing WTAP-mediated GNAS-AS1 m6A modification and then regulating the miR-34a-5p/IGF2BP2 axis.
Sections du résumé
BACKGROUND
BACKGROUND
Acute myeloid leukemia (AML) is a hematopoietic malignancy. Chidamide has shown anti-cancer effect in different malignancies. The function of Chidamide in glycolysis in AML cells remains unclear.
METHODS
METHODS
AML cells were treated with 1000 nM Chidamide for 48 h. The levels of long non-coding RNA-GNAS-AS1, miR-34a-5p, glycolysis-related proteins, and Ras homolog gene family (RhoA)/Rho-associated protein kinase (ROCK) signaling-related proteins were detected by qRT-PCR or western blot. Cell viability and apoptosis were measured by CCK-8 and flow cytometry. Glycolysis levels were measured by assay kits. GNAS-AS1 N6-methyladenosine (m6A) modification level was detected by methylated RNA immunoprecipitation sequencing. The combined targets of miR-34a-5p were validated using a dual-luciferase reporter assay. BALB/C nude mice were selected for subcutaneous tumor validation. Chidamide at a dosage of 25 mg/kg was used in the animal study.
RESULTS
RESULTS
GNAS-AS1 promoted glycolysis in AML cells by upregulating the expression of glycolysis-related proteins and increasing glucose consumption, lactate production, ATP generation, and the extracellular acidification rate. Chidamide treatment suppressed WT1-associated protein (WTAP)-mediated RNA m6A modification of GNAS-AS1. Chidamide downregulated GNAS-AS1 to inhibit glycolysis in AML cells. GNAS-AS1 targeted miR-34a-5p to promote insulin-like growth factor 2 mRNA-binding protein (IGF2BP2) expression. IGF2BP2 inhibition reversed the promoting effect of miR-34a-5p knockdown on glycolysis and RhoA/ROCK pathway in Chidamide-treated cells. GNAS-AS1 overexpression abolished the inhibitory effect of Chidamide on AML tumorigenesis in vivo by modulating the RhoA/ROCK pathway.
CONCLUSION
CONCLUSIONS
Chidamide inhibited glycolysis in AML by repressing WTAP-mediated GNAS-AS1 m6A modification and then regulating the miR-34a-5p/IGF2BP2 axis.
Identifiants
pubmed: 37926762
doi: 10.1007/s40199-023-00482-y
pii: 10.1007/s40199-023-00482-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Hunan Provincial Health Commission 2022 Annual Scientific Research Project
ID : 202203042579
Informations de copyright
© 2023. The Author(s), under exclusive licence to Tehran University of Medical Sciences.
Références
Zhang W, et al. Long non-coding RNA taurine upregulated gene 1 targets miR-185 to regulate cell proliferation and glycolysis in acute myeloid leukemia cells in vitro. Onco Targets Ther. 2020;13:7887–96.
pubmed: 32982274
pmcid: 7493018
doi: 10.2147/OTT.S238189
Ofran Y, Rowe JM. Acute myeloid leukemia in adolescents and young adults: challenging aspects. Acta Haematol. 2014;132(3–4):292–7.
pubmed: 25228554
Chiu CF, et al. T315 decreases acute myeloid leukemia cell viability through a combination of apoptosis induction and autophagic cell death. Int J Mol Sci. 2016;17(8):1337.
pubmed: 27537872
pmcid: 5000734
doi: 10.3390/ijms17081337
Lin L, et al. Chidamide inhibits acute myeloid leukemia cell proliferation by lncRNA VPS9D1-AS1 downregulation via MEK/ERK signaling pathway. Front Pharmacol. 2020;11: 569651.
pubmed: 33192510
pmcid: 7604502
doi: 10.3389/fphar.2020.569651
Bai X, et al. Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miR-33a-5p-LDHA axis. Mol Med Rep. 2019;20(2):1857–65.
pubmed: 31257519
Shouksmith AE, et al. Class I/IIb-selective HDAC inhibitor exhibits oral bioavailability and therapeutic efficacy in acute myeloid leukemia. ACS Med Chem Lett. 2020;11(1):56–64.
pubmed: 31938464
doi: 10.1021/acsmedchemlett.9b00471
Zhang C, et al. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun. 2013;4:2935.
pubmed: 24343302
doi: 10.1038/ncomms3935
Wang JD, et al. Disruption of mitochondrial oxidative phosphorylation by chidamide eradicates leukemic cells in AML. Clin Transl Oncol. 2023;25(6):1805–20.
pubmed: 36899123
doi: 10.1007/s12094-023-03079-8
Gu S, et al. Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia. Exp Hematol Oncol. 2023;12(1):23.
pubmed: 36849955
pmcid: 9972767
doi: 10.1186/s40164-023-00383-5
Zhao S, et al. Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling. Am J Transl Res. 2016;8(7):3169–78.
pubmed: 27508038
pmcid: 4969454
Alvarez-Dominguez JR, Lodish HF. Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis. Blood. 2017;130(18):1965–75.
pubmed: 28928124
pmcid: 5669209
doi: 10.1182/blood-2017-06-788695
Feng Y, et al. LncRNA NR-104098 inhibits AML proliferation and induces differentiation through repressing EZH2 transcription by interacting with E2F1. Front Cell Dev Biol. 2020;8:142.
pubmed: 32296698
pmcid: 7136616
doi: 10.3389/fcell.2020.00142
Li J, et al. LncRNA UCA1 promotes the progression of AML by upregulating the expression of CXCR4 and CYP1B1 by affecting the stability of METTL14. J Oncol. 2022;2022:2756986.
pubmed: 35178087
pmcid: 8847036
Li Z, et al. GNAS-AS1/miR-4319/NECAB3 axis promotes migration and invasion of non-small cell lung cancer cells by altering macrophage polarization. Funct Integr Genomics. 2020;20(1):17–28.
pubmed: 31267263
doi: 10.1007/s10142-019-00696-x
Mi Z, et al. Biomarker potential of lncRNA GNAS-AS1 in osteosarcoma prognosis and effect on cellular function. J Orthop Surg Res. 2021;16(1):470.
pubmed: 34321018
pmcid: 8317387
doi: 10.1186/s13018-021-02611-2
Ding N, et al. Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation. Int J Biol Sci. 2020;16(14):2595–611.
pubmed: 32792859
pmcid: 7415423
doi: 10.7150/ijbs.45886
Dorrance AM, et al. Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia. 2015;29(11):2143–53.
pubmed: 26055302
pmcid: 4633325
doi: 10.1038/leu.2015.139
Bayraktar E, et al. Targeting miRNAs and other non-coding RNAs as a therapeutic approach: an update. Noncoding RNA. 2023;9(2):27.
Xiao Y, Su C, Deng T. miR-223 decreases cell proliferation and enhances cell apoptosis in acute myeloid leukemia via targeting FBXW7. Oncol Lett. 2016;12(5):3531–6.
pubmed: 27900032
pmcid: 5103979
doi: 10.3892/ol.2016.5115
Li S, et al. The comprehensive landscape of miR-34a in cancer research. Cancer Metastasis Rev. 2021;40(3):925–48.
pubmed: 33959850
doi: 10.1007/s10555-021-09973-3
Liu X, Li H. Diagnostic value of miR-34a in bone marrow mononuclear cells of acute myeloid leukemia patients. Clin Lab. 2020;66(3):419–24.
Cheng Y, et al. Identification of circRNA-lncRNA-miRNA-mRNA competitive endogenous RNA network as novel prognostic markers for acute myeloid leukemia. Genes (Basel). 2020;11(8):868.
Wang CH, et al. LncRNA ANRIL promotes cell proliferation, migration and invasion during acute myeloid leukemia pathogenesis via negatively regulating miR-34a. Int J Biochem Cell Biol. 2020;119: 105666.
pubmed: 31830533
doi: 10.1016/j.biocel.2019.105666
Li S, et al. lncARSR sponges miR-34a-5p to promote colorectal cancer invasion and metastasis via hexokinase-1-mediated glycolysis. Cancer Sci. 2020;111(10):3938–52.
pubmed: 32798250
pmcid: 7540992
doi: 10.1111/cas.14617
He X, et al. IGF2BP2 overexpression indicates poor survival in patients with acute myelocytic leukemia. Cell Physiol Biochem. 2018;51(4):1945–56.
pubmed: 30513526
doi: 10.1159/000495719
Wang XQ, et al. Long non-coding RNA GNAS-AS1 promotes cell migration and invasion via regulating Wnt/β-catenin pathway in nasopharyngeal carcinoma. Eur Rev Med Pharmacol Sci. 2020;24(6):3077–84.
pubmed: 32271425
Wang Y, et al. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Mol Cancer. 2019;18(1):174.
pubmed: 31791342
pmcid: 6886219
doi: 10.1186/s12943-019-1105-0
Liu D, et al. IGF2BP2 promotes gastric cancer progression by regulating the IGF1R-RhoA-ROCK signaling pathway. Cell Signal. 2022;94: 110313.
pubmed: 35306138
doi: 10.1016/j.cellsig.2022.110313
Liang X, Xia R. Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia. Oncol Rep. 2022;47(1):26.
Chiu CF, et al. T315 Decreases acute myeloid leukemia cell viability through a combination of apoptosis induction and autophagic cell death. Int J Mol Sci. 2016;17(8):1337.
Chandel NS. Glycolysis. Cold Spring Harb Perspect Biol. 2021;13(5):a040535.
Wang L, et al. Glucose transporter 1 critically controls microglial activation through facilitating glycolysis. Mol Neurodegener. 2019;14(1):2.
pubmed: 30634998
pmcid: 6329071
doi: 10.1186/s13024-019-0305-9
Hay N. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer. 2016;16(10):635–49.
pubmed: 27634447
pmcid: 5516800
doi: 10.1038/nrc.2016.77
Herst PM, et al. The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome. J Leukoc Biol. 2011;89(1):51–5.
pubmed: 20959411
doi: 10.1189/jlb.0710417
Gregory MA, et al. Targeting glutamine metabolism and redox state for leukemia therapy. Clin Cancer Res. 2019;25(13):4079–90.
pubmed: 30940653
pmcid: 6642698
doi: 10.1158/1078-0432.CCR-18-3223
Song K, et al. Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia. Oncol Lett. 2016;12(1):334–42.
pubmed: 27347147
pmcid: 4906727
doi: 10.3892/ol.2016.4600
Gong K, et al. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 2012;443(3):735–46.
pubmed: 22339555
doi: 10.1042/BJ20111685
Kollinerova S, Vassanelli S, Modriansky M. The role of miR-29 family members in malignant hematopoiesis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(4):489–501.
pubmed: 24993745
doi: 10.5507/bp.2014.029
Chen Y, et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol Cancer. 2019;18(1):127.
pubmed: 31438961
pmcid: 6704583
doi: 10.1186/s12943-019-1053-8
Li Z, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N(6)-methyladenosine RNA demethylase. Cancer Cell. 2017;31(1):127–41.
pubmed: 28017614
doi: 10.1016/j.ccell.2016.11.017
Ping XL, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24(2):177–89.
pubmed: 24407421
pmcid: 3915904
doi: 10.1038/cr.2014.3
Jun HH, et al. Association between TP53 genetic polymorphisms and the methylation and expression of miR-34a, 34b/c in colorectal cancer tissues. Oncol Lett. 2019;17(5):4726–34.
pubmed: 30944658
pmcid: 6444414
Xu XP, et al. miR-34a-5p suppresses the invasion and metastasis of liver cancer by targeting the transcription factor YY1 to mediate MYCT1 upregulation. Acta Histochem. 2020;122(6): 151576.
pubmed: 32778238
doi: 10.1016/j.acthis.2020.151576
Chen C, et al. Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis. Oncogene. 2019;38(23):4527–39.
pubmed: 30742065
doi: 10.1038/s41388-019-0735-4
Ho KH, et al. Glycolysis-associated lncRNAs identify a subgroup of cancer patients with poor prognoses and a high-infiltration immune microenvironment. BMC Med. 2021;19(1):59.
pubmed: 33627136
pmcid: 7905662
doi: 10.1186/s12916-021-01925-6
Ma F, et al. Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop. Cancer Lett. 2019;450:63–75.
pubmed: 30771425
doi: 10.1016/j.canlet.2019.02.008
Weng H, et al. The m(6)A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022;40(12):1566-1582.e10.
pubmed: 36306790
doi: 10.1016/j.ccell.2022.10.004
Zhang L, Zhou H, Wei G. miR-506 regulates cell proliferation and apoptosis by affecting RhoA/ROCK signaling pathway in hepatocellular carcinoma cells. Int J Clin Exp Pathol. 2019;12(4):1163–73.
pubmed: 31933931
pmcid: 6947048
Zhang R, et al. Low-intensity pulsed ultrasound modulates RhoA/ROCK signaling of rat mandibular bone marrow mesenchymal stem cells to rescue their damaged cytoskeletal organization and cell biological function induced by radiation. Stem Cells Int. 2020;2020:8863577.
pubmed: 32952571
pmcid: 7482001
doi: 10.1155/2020/8863577